Department of Neurology, NYU Grossman School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USA; Department of Psychiatry, NYU Grossman School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USA.
Department of Psychiatry, NYU Grossman School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USA.
Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):553-568. doi: 10.1016/j.chc.2022.03.008.
Attention-deficit/hyperactivity disorder (ADHD) significantly worsens quality of life and long-term functional outcomes in adults. Individual impairments in adults with ADHD can be further contextualized within considerable costs to society at large. Food and Drug Administration (FDA) approved stimulants and nonstimulant medications can significantly improve ADHD symptoms in adults. In the past 2 decades, the United States FDA has expanded approval of pharmacotherapeutic options for adult ADHD. However, limitations still persist in available psychotropics for certain patient populations such as those with comorbid substance use or cardiovascular illness. Clinicians therefore must appreciate several ongoing investigations into medications with unique mechanisms of action. This article reviews the current FDA approved and emerging medication options while providing guidelines for pharmacologic management of adult ADHD.
注意缺陷多动障碍(ADHD)会显著降低成年人的生活质量和长期功能预后。在一般情况下,成年人的 ADHD 个体损伤可进一步归因于社会的巨大成本。食品和药物管理局(FDA)批准的兴奋剂和非兴奋剂药物可显著改善成年人的 ADHD 症状。在过去的 20 年中,美国 FDA 扩大了对成人 ADHD 治疗选择的批准。然而,对于某些患者群体(如合并物质使用或心血管疾病的患者),现有的精神药物仍然存在局限性。因此,临床医生必须了解几种具有独特作用机制的药物的正在进行的研究。本文综述了目前 FDA 批准和新出现的药物选择,同时为成人 ADHD 的药物治疗管理提供了指导。